Submit an Article
Navigate
Home
Editorial Board
Editorial Policies
Current Volume
Archive
Scientific Integrity
Publication Ethics Statements
Interviews with Outstanding Authors
Newsroom
Sponsored Conferences
Podcast
Contact
Special Collections
Submit an Article
Online ISSN: 1945-4589
Research Paper
|
Volume 13, Issue 17
|
pp. 21102–21121
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
Back to article
Figure 8
(8 of 8)
−
100%
+
Figure 8.
Expression levels of BTK, IκBα, P65 and their phosphorylation proteins in the Jeko-1, Rec-1, and Z138 cells after treating with low-dose BGB-3111, low-dose BTZ, and their combination for 48 h.
